Survival options

Survival:
Split patients by
	Auto select best cutoff
	Trichotomization

Follow up threshold:

Censore at threshold:
Compute median survival:
Export plot data as text:

Restrict analysis to subtypes...

ER status:	IHC:
	Gene chip:
PGR status:	IHC:
HER2 status:	IHC:
	Gene chip:

Molecular subtype:

Grade:
Lymph node status:

Restrict analysis to selected cohorts...

	systemically untreated patients:
	systemically treated patients:
	ER-positive endocrine therapy:
	chemotherapy:
	do not use cohorts

Compare datasets

METABRIC: long follow-up (median: 94 months), average characteristics (78% ER positive, 12% HER2 positive), treatment data available for this dataset only!
TCGA: very short follow-up (median only 25 months), no grade.
GSE40267: almost exclusively ER negative patients (92%).
GSE19783: nodal status not available, 38% ER negative, high proportion of HER2 positive patients (18%).

By using the services, you agree to be bound by the Terms of Use.

Display results in new window:

Please note: the generated p value does not include correction for multiple hypothesis testing by default.

Please kindly cite our latest paper to support further development: Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer, Computational and Structural Biotechnology Journal, 2021;19:4101-4109, https://doi.org/10.1016/j.csbj.2021.07.014

Plot line thickness:
Plot text size:
Plot text format:
Plot title:
P-value position:
Legend position:
Export plot data as text:
Generate high resolution TIFF file:
Invert HR values below 1:

Processing...

Survival options

Restrict analysis to subtypes...

Restrict analysis to selected cohorts...

Compare datasets